This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

These meetings may contain promotional information.

As per the IPHA Code of Practice, this invitation is extended to Healthcare Professionals only.

Filter by
Reset all
Products
  • Nucala

  • Relvar

  • Shingrix

  • Above Brand

  • Zejula

Therapy
  • Respiratory

  • Vaccines

  • Oncology

Duration
  • 30 minutes

  • 1 hour

  • 1.5 hours

  • 2 hours

Zejula GyncancerXchange ESGO Meet the Experts
In this Video, Professor Jonathan A. Ledermann will discuss clinical considerations for selection of PARPi therapy for women with advanced ovarian cancer, the importance of an integrated patient care approach and patient considerations for dosing, administration and optimising adherence to therapy.
12 Jan, 2023 | 00:00 GMT
PM-IE-NRP-WCNT-250001 | Date of preparation January 2025
Filter By
Reset all
Products
  • Nucala

  • Relvar

  • Shingrix

  • Above Brand

  • Zejula

Therapy
  • Respiratory

  • Vaccines

  • Oncology

Duration
  • 30 minutes

  • 1 hour

  • 1.5 hours

  • 2 hours

Zejula GyncancerXchange ESGO Meet the Experts
In this Video, Professor Jonathan A. Ledermann will discuss clinical considerations for selection of PARPi therapy for women with advanced ovarian cancer, the importance of an integrated patient care approach and patient considerations for dosing, administration and optimising adherence to therapy.
12 Jan, 2023 o 00:00 GMT
PM-IE-NRP-WCNT-250001 | Date of preparation January 2025
Events and webinars with GSK

Events and webinars with GSK

By sharing our knowledge, we hope we can ultimately improve the lives of patients.  To do that we’ve developed the GSK website so healthcare professionals can have easy access to our resources, tools, advice, opinion and news.